Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on January 28th, 2023%
Data in the chart are compiled by PatentSight, a service of LexisNexis, that show the seven leading holders of machine learning and other A.I. patents by company in 2017 and 2021. . . . → Read More: Infographic – Chinese Companies Lead in A.I. Patents
By Alan, on December 30th, 2022%
A new enterprise is formed to develop gene-editing therapies for mitochondrial disorders, rare inherited mutations in the energy centers of cells. . . . → Read More: Company Started for Gene Editing Rare Inherited Diseases
By Alan, on December 27th, 2022%
A discoverer of therapeutic peptides signed licensing deals in the past few days with two drug makers that could bring the company as much as $3.3 billion. . . . → Read More: Peptide Discovery Company to Gain $3.3B in Licensing Deals
By Alan, on November 17th, 2022%
A developer of cancer treatments triggered by tumor chemistry is partnering with biologic drug maker Regeneron on dual-action cancer immunotherapies. . . . → Read More: Biotech, Regeneron in $2B Cancer Antibody Deal
By Alan, on November 15th, 2022%
A start-up enterprise seeks to make drugs for treating rare diseases more readily available to physicians and patients in Europe. . . . → Read More: Company to Boost Orphan Drugs in Europe
By Alan, on November 9th, 2022%
A company developing non-invasive ultrasound treatments for treating skin disorders and removing tattoos received a patent for its technology. . . . → Read More: Patent Awarded for Focused Ultrasound Skin Treatments
By Alan, on October 10th, 2022%
A company making precision therapies for neurological disorders is acquiring rights to a compound first designed as a treatment for cancer, inflammation, and oxidative stress. . . . → Read More: Drug Licensed for Precision Autism Spectrum Therapies
By Alan, on October 3rd, 2022%
A biotechnology company developing gene-edited therapies for bacterial infections in the gut received a U.S. patent for viruses engineered as treatments. . . . → Read More: Patent Issued for Crispr-Edited Viruses in Microbiome
By Alan, on September 27th, 2022%
A new company is acquiring a technology using genome-edited tadpoles that finds current drugs addressing precise genetic conditions underlying rare diseases. . . . → Read More: Start-Up Licenses Gene-Edited Drug Discovery Tech.
By Alan, on August 11th, 2022%
A genetic technology for synthesizing cannabinoid compounds without cannabis cells was licensed to a company spun-off from the lab that developed the process. . . . → Read More: Cannabinoid Synthesis Process Licensed to Spin-Off Company
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|